Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miyarisan-BM for Motor and Non-motor Symptoms in Parkinson's Disease
NCT06548256Recruiting
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Open-label trial of clostridium butyricum in Parkinson's disease (PD) (2 arms), sponsored by Kaohsiung Medical University Chung-Ho Memorial Hospital. Primary endpoints: MDS-Unified Parkinson's Disease Rating Scale Part 3 at 24 months, Hamilton Depression Rating Scale at 24 months and 1 more. Started Oct 2023; status: recruiting.
02
Drugs
clostridium butyricum
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06548256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06548256.